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Department of Psychiatry, University of British Columbia, CanadaFlibanserin, a drug with mixed effects on serotonergic and dopami-
nergic neurotransmitter systems, has recently been recommended for
FDA approval, albeit withmany restrictions, for the treatment of low sex-
ual desire in premenopausal women. The sexual side effects of antide-
pressants with at least partially known mechanisms of action indicate
that ﬂibanserin should enhance sexual response. Rather than illustrating
translation of knowledge from bench to bedside, the reality is less dra-
matic – as is ﬂibanserin's efﬁcacy.
Ineffective as an antidepressant, but noted to have pro-sexual side
effects, ﬂibanserin was trialed for this new indication in the early
2000's. The FDA denied Boehringer Ingelheim's application for approval
of ﬂibanserin for hypoactive sexual desire disorder (HSDD) inwomen in
2010 as two phase 3 trials failed to show statistically signiﬁcant beneﬁt
on one of two co-primary endpoints — a daily diary assessment of
desire. Sprout Pharmaceuticals reapplied in 2013 with data from a
third trial which used a different co-primary endpoint – a retrospective
assessment of desire over the previous 4 weeks. Due both to safety
concerns, which include hypotension, syncope, somnolence, fatigue,
and potential carcinogenicity and to the short duration of studies and
questionable accuracy of 4 week recall along with marginal efﬁcacy,
approval was denied and additional safety studies recommended.
Beneﬁt across all phase 3 studies averaged a placebo-corrected increase
of ‘satisfactory sexual events’ by 0.5 to 1 per month and an increase of
0.3 on the retrospective desire scale (range 1.2–6.0). Surprisingly,
despite lack of additional efﬁcacy data, but with data ruling out driving
impairment and assessing alcohol's enhancement of side effects in 23
men and 2 women, on June 4, 2015, an FDA advisory committee voted
18 to 6 to accept ﬂibanserin's approval, but with reservations. Fifteen
members endorsing its approval declared their reluctance to do so.
An additional concern is that trial participants had no clear diagnosis
of sexual disorder as is currently understood. Growing concern that
HSDD criteria are not appropriate for women led to interim deﬁnitions
of low desire in 2003, and to an ofﬁcially changed deﬁnition in 2013
(American Psychiatric Association, 2013). A state of ongoing sexual
desire between sexual experiences is de-emphasized. Responsive desire
triggered by sexual stimuli including those received during sexual
encounters is now recognized (Both et al., 2007; Stoléru et al., 2012).
Beginning partnered sexual activity for reasons other than ‘desire’ has
been clearly documented as the most common scenario in both young
(Meston and Buss, 2007) and older women (Cain et al., 2003). Patholo-
gy now focuses on the inability to trigger desire and arousal during
sexual experiences. Participants in ﬂibanserin studies, however, report-
ed 2 to 3 rewarding sexual experiences each month at baseline.http://dx.doi.org/10.1016/j.ebiom.2015.08.009
2352-3964/© 2015 The Authors. Published by Elsevier B.V. This is an open access article underBackwards translation of sexual side effects ofmedications identiﬁes
neurotransmitters involved in the brain's sexual response system, the
sensitivity of which is highly variable. There is robust evidence that sex-
ual and non-sexual distractions, fatigue, low self-image, depressive
thoughts, anxiety and stress (Cyranowski et al., 2004; de Jong, 2009;
Nelson and Purdon, 2011; Nobre and Pinto-Gouveia, 2008) can lessen
that sensitivity to inhibit sexual arousal, pleasurable physical sexual
sensations and orgasms. Sexual activity is not rewarding and sexual
motivation fades: satisfactory sexual experiences cease. Women with
this most common type of dysfunction (Brotto, 2010), a muting of
all phases of sexual response, were not the cohort recruited for the
ﬂibanserin trials.
To date there is no example of ‘bench to bed’ knowledge transla-
tion of drugs to beneﬁt sexual dysfunction. Sildenaﬁl's success in
managing erectile dysfunction (ED) resulted from capitalizing on a
pro-sexual side effect of a putative antihypertensive drug that failed
for that indication. The activity of nitric oxide (NO), a major neuro-
transmitter underlying the vaso-dilatation of erection, can be
prolonged by inhibiting phosphodiesterase type 5. The latter
inhibits cGMP whose production is initiated by NO from autonomic
nerve terminals in the penile sinusoidal spaces in response to sexual
arousal. Providing a man is sexually excited and that the signaling
from his brain through the spinal cord to autonomic nerve endings
in cavernosal tissue is relatively intact, the erectile mechanism is
enhanced. Phosphodiesterase type 5 inhibitors cause similar increase
in neurogenic vasodilatation in clitoral tissue, but with minimal impact
on women's sexual concerns: reduced clitoral engorgement rarely un-
derlies women's sexual dysfunction. The degree of genital congestion
correlates poorly with women's subjective arousal, and is not typically
the pleasant reassurance of and contributor to subjective arousal as it
is for men.
Future medications for ED may emerge from lab-based discovery of
other players additional to NO. The age-related increase in rho kinase,
whichmodulates the sensitivity of cavernosal smoothmuscle to intracel-
lular calcium, may allow inhibitors of rho A/rho kinase signaling to
beneﬁt ED. Translating knowledge of genes coding for the various mole-
cules affecting cavernosal smooth muscle relaxation allows exploration
of gene therapy for ED.
Backwards translation of medications' sexual side effects allows
choice of more sex-friendly antidepressants to improve compliance.
Drugs which are not 5HT2C or 5HT2A agonists but activate 5HT1A recep-
tors minimize sexual harm. Examples include trazodone, a 5-HT2A
receptor antagonist and 5-HT1A partial agonist, and mirtazapine, athe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
773R. Basson et al. / EBioMedicine 2 (2015) 772–773noradrenergic and speciﬁc serotonergic antidepressant. Unlike SSRIs,
SNRIs, and MAOIs, mirtazapine does not activate 5-HT2A, 5-HT2C, and 5-
HT3 receptors, beneﬁting sleep, appetite and sexual function. Gepirone
and a new SSRI, vilazadone, both with 5-HT1A partial agonist action,
may also prove sex-friendly. Neither bupropion, which prevents reup-
take of noradrenaline and dopamine, nor meclobamide, a reversible
monoamine oxidase inhibitor, nor agomelatine, aMT1 andMT2 agonist,
typically harm sexual response.
Conversely, medications which activate 5HT2C and/or antagonize
5HT1A receptors are used off label to delay ejaculation: dapoxetene
(an unsuccessful antidepressant), is approved for this indication.
Further research into the neuroendocrinology of sexual response is
needed. This would include the aspect that women so frequently ﬁnd
dysfunctional – namely pleasurable and relatively intense psychological
and physical arousal such that desire formore of the same is triggered to
allow orgasms and pleasurable outcomes. Rewarding sex provides its
own incentive for its repetition: no ‘desire drug’ needed.
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